Ardent Health Reports Third Quarter 2024 Results
Ardent Health (NYSE: ARDT) reported strong Q3 2024 results with total revenue increasing 5.2% to $1.45 billion. Net income reached $26 million ($0.19 per share), while Adjusted EBITDA grew 15.3% to $98 million with margin expansion of 50bps to 6.7%. The company saw a 3.8% increase in adjusted admissions and 0.9% growth in net patient service revenue per adjusted admission. Based on strong performance, Ardent raised its full-year 2024 guidance, increasing the Adjusted EBITDA midpoint by 2% and improving revenue outlook to $5.8-5.875 billion.
Ardent Health (NYSE: ARDT) ha riportato risultati solidi per il terzo trimestre del 2024, con un aumento del fatturato totale del 5,2% a 1,45 miliardi di dollari. L'utile netto ha raggiunto 26 milioni di dollari (0,19 dollari per azione), mentre l'EBITDA rettificato è aumentato del 15,3% a 98 milioni di dollari, con un'espansione del margine di 50 punti base a 6,7%. L'azienda ha registrato un incremento del 3,8% nelle ammissioni rettificate e una crescita dello 0,9% nel fatturato dei servizi ai pazienti netti per ammissione rettificata. Sulla base delle performance solide, Ardent ha rivisto al rialzo le sue previsioni per l'intero anno 2024, aumentando il punto medio dell'EBITDA rettificato del 2% e migliorando le prospettive di fatturato a 5,8-5,875 miliardi di dollari.
Ardent Health (NYSE: ARDT) reportó resultados sólidos para el tercer trimestre de 2024, con un aumento del 5.2% en los ingresos totales, alcanzando 1.45 mil millones de dólares. El ingreso neto llegó a 26 millones de dólares (0.19 dólares por acción), mientras que el EBITDA ajustado creció un 15.3% hasta 98 millones de dólares, con una expansión del margen de 50 puntos base a 6.7%. La compañía vio un aumento del 3.8% en las admisiones ajustadas y un crecimiento del 0.9% en los ingresos netos por servicios a pacientes por admisión ajustada. Basado en un desempeño sólido, Ardent elevó su guía para todo el año 2024, aumentando el punto medio del EBITDA ajustado en un 2% y mejorando la perspectiva de ingresos a 5.8-5.875 mil millones de dólares.
Ardent Health (NYSE: ARDT)는 2024년 3분기 강력한 실적을 보고하며 총 수익이 5.2% 증가하여 14.5억 달러에 달했습니다. 순이익은 2,600만 달러 (주당 0.19 달러)에 도달했으며, 조정 EBITDA는 15.3% 증가하여 9,800만 달러로 늘었고, 마진은 50bp 증가하여 6.7%에 이르렀습니다. 회사는 조정된 입원 수가 3.8% 증가하고 조정된 입원당 순환자 서비스 수익이 0.9% 성장한 것을 보고했습니다. 강한 실적을 바탕으로 Ardent는 2024년 전체 연도 가이던스를 상향 조정하고, 조정 EBITDA 중간값을 2% 증가시켰으며 수익 전망을 58-58.75억 달러로 개선했습니다.
Ardent Health (NYSE: ARDT) a annoncé de solides résultats pour le troisième trimestre 2024, avec une augmentation du chiffre d'affaires total de 5,2% à 1,45 milliard de dollars. Le bénéfice net a atteint 26 millions de dollars (0,19 dollar par action), tandis que l'EBITDA ajusté a augmenté de 15,3% pour atteindre 98 millions de dollars, avec une expansion de la marge de 50 points de base à 6,7%. L'entreprise a constaté une augmentation de 3,8% des admissions ajustées et une croissance de 0,9% des revenus nets des services aux patients par admission ajustée. Sur la base de performances solides, Ardent a rehaussé ses prévisions pour l'année 2024, augmentant le point médian de l'EBITDA ajusté de 2% et améliorant les perspectives de revenus à 5,8-5,875 milliards de dollars.
Ardent Health (NYSE: ARDT) hat starke Ergebnisse für das dritte Quartal 2024 gemeldet, mit einem Anstieg des Gesamterlöses um 5,2% auf 1,45 Milliarden Dollar. Der Nettogewinn erreichte 26 Millionen Dollar (0,19 Dollar pro Aktie), während das bereinigte EBITDA um 15,3% auf 98 Millionen Dollar wuchs, mit einer Margenausweitung von 50 Basispunkten auf 6,7%. Das Unternehmen verzeichnete einen Anstieg der bereinigten Aufnahmen um 3,8% und ein Wachstum der Nettoumsätze aus Patientenservices pro bereinigter Aufnahme um 0,9%. Aufgrund der starken Leistung hat Ardent seine Prognose für das gesamte Jahr 2024 angehoben, den Mittelwert des bereinigten EBITDA um 2% erhöht und die Umsatzerwartung auf 5,8-5,875 Milliarden Dollar verbessert.
- Revenue growth of 5.2% to $1.45 billion in Q3 2024
- Adjusted EBITDA increased 15.3% with margin expansion of 50bps
- Net income grew to $26 million ($0.19 per share) from $21 million
- Admissions increased 6.4% year-over-year
- Strong liquidity position with $851 million available
- Reduced interest expenses through term loan repricing, saving $5 million annually
- Strategic transfer of oncology services resulted in $10 million revenue reduction
- Lower net income guidance due to delayed insurance proceeds collection
- Slower growth in net patient service revenue per adjusted admission at 0.9%
Insights
The Q3 results demonstrate strong operational performance with notable improvements across key metrics. Revenue grew 5.2% to
The balance sheet remains healthy with
Key operational metrics show robust growth with adjusted admissions up
The company's ability to maintain growth despite transitioning certain oncology services and the impact of prior year's one-time revenue items (
Third Quarter 2024 Operating and Financial Summary
All comparisons are versus the same prior year period, unless otherwise noted. See the footnotes to the Operating Statistics table of this press release for definitions of the metrics below and a full list of key operating metrics.
Total Revenue
+ |
Net Income Attributable to Ardent Health
|
Adjusted EBITDA(1)
+ |
Cash Flow from Operating Activities
|
Adjusted Admissions
|
Net Patient Service Revenue per Adjusted Admission
|
Adjusted EBITDAR(1)
|
Increase Full-Year 2024 Adjusted EBITDA(1) & Revenue Guidance |
(1) Adjusted EBITDA and Adjusted EBITDAR are non-GAAP financial measures. See "Supplemental Non-GAAP Financial Information" for reconciliations of non-GAAP measures to their most comparable GAAP financial measures.
Strong Third Quarter Results – Raising 2024 Guidance
|
Financial Performance Summary
Total revenue for the third quarter of 2024 grew
The third quarter of 2023 benefited from the recognition of approximately
For the third quarter of 2024, net income attributable to Ardent Health was
Adjusted EBITDA for the third quarter of 2024 increased
Operating Performance Summary
The following table provides a summary of certain key operating metrics for the third quarter of 2024 compared to the same prior year period. See the footnotes to the Operating Statistics table of this press release for definitions of the metrics below and a full list of key operating metrics.
|
Three Months Ended September 30, |
|
|
|||||
|
|
2024 |
|
|
2023 |
|
% Change |
|
Adjusted admissions |
|
86,833 |
|
|
83,643 |
|
3.8 |
% |
Admissions |
|
39,568 |
|
|
37,191 |
|
6.4 |
% |
Inpatient surgeries |
|
8,871 |
|
|
8,826 |
|
0.5 |
% |
Outpatient surgeries |
|
23,220 |
|
|
23,164 |
|
0.2 |
% |
Total surgeries |
|
32,091 |
|
|
31,990 |
|
0.3 |
% |
Emergency room visits |
|
161,343 |
|
|
157,182 |
|
2.6 |
% |
Net patient service revenue per adjusted admission |
$ |
16,312 |
|
$ |
16,174 |
|
0.9 |
% |
-
Admissions for the third quarter of 2024 increased
6.4% year-over-year, modestly faster than the comparable5.3% growth in the first half of 2024. The increase was primarily attributable to growth in general medicine, including strong growth in pulmonology and gastroenterology cases, as well as the ongoing impact of the two-midnight rule. -
Surgeries for the third quarter of 2024 increased
0.3% year-over-year, an improvement from a comparable decline of1.9% during the first half of 2024. The year-over-year growth in total surgeries of0.3% reflected increases of0.5% and0.2% in inpatient and outpatient surgeries, respectively. As expected, the Company’s strategic service line optimization efforts continued to be a volume headwind for lower margin services, including otolaryngology; however, growth in higher acuity lines, including orthopedics, contributed to a more favorable case mix. -
Net patient service revenue per adjusted admission for the third quarter of 2024 increased
0.9% year-over-year. The growth rate would have been over3.0% , excluding the aforementioned$25 million $10 million
Balance Sheet, Cash Flow & Liquidity Update
As previously announced, during the third quarter, the Company amended its term loan credit agreement with lenders to reprice its term loans. The repricing is expected to generate approximately
As of September 30, 2024, the Company had total cash and cash equivalents of
During the third quarter of 2024, net cash provided by operating activities was
Other Matters
The Company acknowledges the devastation left by Hurricane Helene and Hurricane Milton across the southeastern
Financial Guidance
The Company is updating its financial guidance for the full year 2024, increasing revenue and adjusted EBITDA to reflect third quarter results and continued confidence in its business execution. The Company is lowering net income guidance due to a delay in the expected timing of collecting business insurance proceeds related to the cybersecurity incident, partially offset by higher adjusted EBITDA. The Company's expectation for its business insurance claim remains unchanged, with additional proceeds expected to be collected in 2025. All guidance is current as of the time provided and is subject to change.
|
Full Year 2024 Projected |
||||||
(Dollars in millions, except per share amount) |
Previous Guidance |
|
New Guidance |
||||
Total revenue |
|
— |
|
|
|
— |
|
Net income attributable to Ardent Health Partners, Inc. |
|
— |
|
|
|
— |
|
Adjusted EBITDA |
|
— |
|
|
|
— |
|
Rent expense payable to REITs |
|
— |
|
|
|
— |
|
Diluted earnings per share |
|
— |
|
|
|
— |
|
Adjusted admissions growth |
|
— |
|
|
|
— |
|
Net patient service revenue per adjusted admission growth |
|
— |
|
|
|
— |
|
Capital expenditures |
|
— |
|
|
|
— |
|
| ______________________________ | ||
| 1 | Lease-adjusted net leverage is defined as the Company's net debt as of September 30, 2024, plus 8x trailing twelve-month real estate investment trust ("REIT") rent expense as of the end of the third quarter of 2024, divided by trailing twelve month Adjusted EBITDAR as of September 30, 2024. |
|
The Company’s forecasted guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy. This is due to the inherent difficulty of forecasting the timing or amount of various items that have not yet occurred and are out of the Company’s control or cannot be reasonably predicted.
Third Quarter 2024 Results Conference Call
The Company will host a conference call to discuss its third quarter financial results on November 7, 2024, at 9:00 a.m. Eastern Time. A webcast of the conference call will be available in the Investor Relations section of the Company’s corporate website at https://ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download, and install any necessary audio software.
To participate in the live teleconference: |
|
United States Live: |
1-888-596-4144 |
International Live: |
1-646-968-2525 |
Access Code: |
4437657 |
To listen to a replay of the teleconference, which will be available through November 14, 2024: |
|
United States Replay: |
1-800-770-2030 |
International Replay: |
1-609-800-9909 |
Access Code: |
4437657 |
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the
Supplemental Non-GAAP Financial Information
We have included certain financial measures in this press release that have not been prepared in a manner that complies with
- Adjusted EBITDA. Adjusted EBITDA is defined as net income plus (i) provision for income taxes, (ii) interest expense and (iii) depreciation and amortization expense (or EBITDA), as adjusted to deduct noncontrolling interest earnings, and excludes the effects of losses on the extinguishment and modification of debt; other non-operating losses (gains); Cybersecurity Incident recoveries, net of incremental information technology and litigation costs; restructuring, exit and acquisition-related costs; expenses incurred in connection with the implementation of Epic Systems ("Epic"), our integrated health information technology system; equity-based compensation expense; and loss (income) from disposed operations.
Adjusted EBITDA is a non-GAAP performance measure used by our management and external users of our financial statements, such as investors, analysts, lenders, rating agencies and other interested parties, to evaluate companies in our industry. Adjusted EBITDA is a performance measure that is not defined under GAAP and is presented in this press release because our management considers it an important analytical indicator that is commonly used within the healthcare industry to evaluate financial performance and allocate resources. Further, our management believes that Adjusted EBITDA is a useful financial metric to assess our operating performance from period to period by excluding certain material non-cash items and unusual or non-recurring items that we do not expect to continue in the future and certain other adjustments we believe are not reflective of our ongoing operations and our performance.
Because not all companies use identical calculations, our presentation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies. While we believe this is a useful supplemental performance measure for investors and other users of our financial information, you should not consider Adjusted EBITDA in isolation or as a substitute for net income or any other items calculated in accordance with GAAP. Adjusted EBITDA has inherent material limitations as a performance measure, because it adds back certain expenses to net income, resulting in those expenses not being taken into account in the performance measure. We have borrowed money, so interest expense is a necessary element of our costs. Because we have material capital and intangible assets, depreciation and amortization expense are necessary elements of our costs. Likewise, the payment of taxes is a necessary element of our operations. Because Adjusted EBITDA excludes these and other items, it has material limitations as a measure of our performance.
- Adjusted EBITDAR. Adjusted EBITDAR is defined as Adjusted EBITDA further adjusted to add back rent expense payable to REITs, which consists of rent expense pursuant to the master lease agreement (the "Ventas Master Lease") with Ventas, Inc. ("Ventas"), lease agreements associated with the MOB Transactions (defined below) and a lease arrangement with Medical Properties Trust, Inc. ("MPT") for the Hackensack Meridian Mountainside Medical Center.
Adjusted EBITDAR is a commonly used non-GAAP valuation measure used by our management, research analysts, investors and other interested parties to evaluate and compare the enterprise value of different companies in our industry. Adjusted EBITDAR excludes: (1) certain material noncash items and unusual or non-recurring items that we do not expect to continue in the future; (2) certain other adjustments that do not impact our enterprise value; and (3) rent expense payable to our REITs. We operate 30 acute care hospitals, 12 of which we lease from two REITs, Ventas and MPT, pursuant to long-term lease agreements. Additionally, during 2022, we completed the sale of 18 medical office buildings to Ventas in exchange for
Because not all companies use identical calculations, our presentation of Adjusted EBITDAR may not be comparable to other similarly titled measures of other companies. While we believe this is a useful supplemental valuation measure for investors and other users of our financial information, you should not consider Adjusted EBITDAR in isolation or as a substitute for net income or any other items calculated in accordance with GAAP. Adjusted EBITDAR has inherent material limitations as a valuation measure, because it adds back certain expenses to net income, resulting in those expenses not being taken into account in the valuation measure. The payment of taxes and rent is a necessary element of our valuation. Because Adjusted EBITDAR excludes these and other items, it has material limitations as a measure of our valuation.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. Forward-looking statements include all statements that are not historical facts. The words "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek," "foreseeable," the negative version of these words, or similar terms and phrases are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the full year 2024 and other statements that are not historical facts. These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: (1) changes in government healthcare programs, including Medicare and Medicaid and supplemental payment programs and state directed payment arrangements; (2) reduction in the reimbursement rates paid by commercial payors, our inability to retain and negotiate favorable contracts with private third-party payors, or an increasing volume of uninsured or underinsured patients; (3) the highly competitive nature of the healthcare industry; (4) inability to recruit and retain quality physicians, as well as increasing cost to contract with hospital-based physicians; (5) increased labor costs resulting from increased competition for staffing or a continued or increased shortage of experienced nurses; (6) changes to physician utilization practices and treatment methodologies and third party-payor controls designed to reduce inpatient services or surgical procedures that impact demand for medical services; (7) continued industry trends toward value-based purchasing, third party payor consolidated and care coordination among healthcare providers; (8) loss of key personnel, including key members of our senior management team; (9) our failure to comply with complex laws and regulations applicable to the healthcare industry or to adjust our operations in response to changing laws and regulations; (10) inability to successfully complete acquisitions or strategic joint ventures (“JVs”) or inability to realize all of the anticipated benefits, including anticipated synergies, of past acquisitions and the risk that transactions may not receive necessary government clearances; (11) failure to maintain existing relationships with JV partners or enter into relationships with additional healthcare system partners; (12) the impact of known and unknown claims brought against our hospitals, physician practices, outpatient facilities or other business operations or against healthcare providers that provide services at our facilities; (13) the impact of government investigations, claims, audits, whistleblower and other litigation; (14) the impact of any security incidents affecting us or any third-party vendor upon which we rely; (15) inability or delay in our efforts to construct, acquire, sell, renovate or expand our healthcare facilities; (16) our failure to comply with federal and state laws relating to Medicare and Medicaid enrollment, permit, licensing and accreditation requirements, or the expansion of existing or the enactment of new laws or regulation relating to permit, licensing and accreditation requirements; (17) failure to obtain drugs and medical supplies at favorable prices or sufficient volumes; (18) operational, legal and financial risks associated with outsourcing functions to third parties; (19) sensitivity to regulatory, economic and competitive conditions in the states in which our operations are heavily concentrated; (20) decreased demand for our services provided due to factors beyond our control, such as seasonal fluctuations in the severity of critical illnesses, pandemic, epidemic or widespread health crisis; (21) inability to accurately estimate market opportunity and forecasts of market growth; (22) general economic and business conditions, both nationally and in the regions in which we operate; (23) the impact of seasonal or severe weather conditions and climate change; (24) inability to demonstrate meaningful use of Electronic Health Record technology; (25) inability to continually enhance our hospitals with the most recent technological advances in diagnostic and surgical equipment; (26) effects of current and future health reform initiatives, including the Affordable Care Act, and the potential for changes to the Affordable Care Act, its implementation or its interpretation (including through executive orders and court challenges); (27) legal and regulatory restrictions on certain of our hospitals that have physician owners; (28) risks related to the Ventas Master Lease and its restrictions and limitations on our business; (29) the impact of our significant indebtedness, including our ability to comply with certain debt covenants and other significant operating and financial restrictions imposed on us by the agreements governing our indebtedness, and the effects that variable interest rates, and general economic factors could have on our operations, including our potential inability to service our indebtedness; (30) conflicts of interest with certain of our existing large stockholders; (31) effects of changes in federal tax laws; (32) increased costs as a result of operating as a public company; (33) risks related to maintaining an effective system of internal controls; (34) volatility of our share price and size of the public market for our common stock; (35) our guidance differing from actual operating and financial performance; (36) the results of our efforts to use technology, including artificial intelligence, to drive efficiencies and quality initiatives and enhance patient experience; (37) the impact of recent decisions of the
Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to put undue reliance on any forward-looking statements, which speak only as of the date of this press release. Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of unanticipated events. All references to “Company,” “Ardent Health,” “we,” “our” and “us” as used throughout this release refer to Ardent Health Partners, Inc. and its affiliates, unless stated otherwise or indicated by context.
Ardent Health Partners, Inc. Condensed Consolidated Income Statements (Unaudited; Dollars in thousands, except per share amounts) |
||||||||||||
|
Three Months Ended September 30, |
|||||||||||
|
2024 |
|
2023 |
|||||||||
|
Amount |
|
% |
|
Amount |
|
% |
|||||
Total revenue |
$ |
1,449,817 |
|
|
100.0 |
% |
|
$ |
1,377,727 |
|
100.0 |
% |
Expenses: |
|
|
|
|
|
|
|
|||||
Salaries and benefits |
|
635,223 |
|
|
43.8 |
% |
|
|
595,580 |
|
43.2 |
% |
Professional fees |
|
274,223 |
|
|
18.9 |
% |
|
|
246,540 |
|
17.9 |
% |
Supplies |
|
251,862 |
|
|
17.4 |
% |
|
|
249,548 |
|
18.1 |
% |
Rents and leases |
|
26,410 |
|
|
1.8 |
% |
|
|
24,506 |
|
1.8 |
% |
Rents and leases, related party |
|
37,249 |
|
|
2.6 |
% |
|
|
36,413 |
|
2.6 |
% |
Other operating expenses |
|
117,700 |
|
|
8.2 |
% |
|
|
124,642 |
|
9.1 |
% |
Government stimulus income |
|
— |
|
|
0.0 |
% |
|
|
— |
|
0.0 |
% |
Interest expense |
|
14,629 |
|
|
1.0 |
% |
|
|
19,041 |
|
1.4 |
% |
Depreciation and amortization |
|
36,771 |
|
|
2.5 |
% |
|
|
35,488 |
|
2.6 |
% |
Loss on extinguishment and modification of debt |
|
1,490 |
|
|
0.1 |
% |
|
|
— |
|
0.0 |
% |
Other non-operating gains |
|
(2,807 |
) |
|
(0.2 |
)% |
|
|
— |
|
0.0 |
% |
Total operating expenses |
|
1,392,750 |
|
|
96.1 |
% |
|
|
1,331,758 |
|
96.7 |
% |
Income before income taxes |
|
57,067 |
|
|
3.9 |
% |
|
|
45,969 |
|
3.3 |
% |
Income tax expense |
|
11,062 |
|
|
0.7 |
% |
|
|
7,261 |
|
0.5 |
% |
Net income |
|
46,005 |
|
|
3.2 |
% |
|
|
38,708 |
|
2.8 |
% |
Net income attributable to noncontrolling interests |
|
19,683 |
|
|
1.4 |
% |
|
|
17,870 |
|
1.3 |
% |
Net income attributable to Ardent Health Partners, Inc. |
$ |
26,322 |
|
|
1.8 |
% |
|
$ |
20,838 |
|
1.5 |
% |
|
|
|
|
|
|
|
|
|||||
Net income per share: |
|
|
|
|
|
|
|
|||||
Basic |
$ |
0.19 |
|
|
|
|
$ |
0.17 |
|
|
||
Diluted |
$ |
0.19 |
|
|
|
|
$ |
0.17 |
|
|
||
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
|||||
Basic |
|
137,107,595 |
|
|
|
|
|
126,115,301 |
|
|
||
Diluted |
|
137,542,995 |
|
|
|
|
|
126,115,301 |
|
|
||
Ardent Health Partners, Inc. Condensed Consolidated Income Statements (Unaudited; Dollars in thousands, except per share amounts) |
|||||||||||||
|
Nine Months Ended September 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
||||||
|
Amount |
|
% |
|
Amount |
|
% |
||||||
Total revenue |
$ |
4,359,783 |
|
|
100.0 |
% |
|
$ |
4,063,449 |
|
|
100.0 |
% |
Expenses: |
|
|
|
|
|
|
|
||||||
Salaries and benefits |
|
1,880,790 |
|
|
43.1 |
% |
|
|
1,785,939 |
|
|
44.0 |
% |
Professional fees |
|
810,820 |
|
|
18.6 |
% |
|
|
715,111 |
|
|
17.6 |
% |
Supplies |
|
769,034 |
|
|
17.6 |
% |
|
|
743,713 |
|
|
18.3 |
% |
Rents and leases |
|
76,251 |
|
|
1.7 |
% |
|
|
73,230 |
|
|
1.8 |
% |
Rents and leases, related party |
|
111,413 |
|
|
2.6 |
% |
|
|
108,914 |
|
|
2.7 |
% |
Other operating expenses |
|
354,851 |
|
|
8.2 |
% |
|
|
342,026 |
|
|
8.3 |
% |
Government stimulus income |
|
— |
|
|
0.0 |
% |
|
|
(8,463 |
) |
|
(0.2 |
)% |
Interest expense |
|
52,050 |
|
|
1.2 |
% |
|
|
55,854 |
|
|
1.4 |
% |
Depreciation and amortization |
|
108,434 |
|
|
2.5 |
% |
|
|
104,860 |
|
|
2.6 |
% |
Loss on extinguishment and modification of debt |
|
3,388 |
|
|
0.1 |
% |
|
|
— |
|
|
0.0 |
% |
Other non-operating gains |
|
(3,062 |
) |
|
(0.1 |
)% |
|
|
(522 |
) |
|
0.0 |
% |
Total operating expenses |
|
4,163,969 |
|
|
95.5 |
% |
|
|
3,920,662 |
|
|
96.5 |
% |
Income before income taxes |
|
195,814 |
|
|
4.5 |
% |
|
|
142,787 |
|
|
3.5 |
% |
Income tax expense |
|
36,997 |
|
|
0.9 |
% |
|
|
24,591 |
|
|
0.6 |
% |
Net income |
|
158,817 |
|
|
3.6 |
% |
|
|
118,196 |
|
|
2.9 |
% |
Net income attributable to noncontrolling interests |
|
62,678 |
|
|
1.4 |
% |
|
|
60,139 |
|
|
1.5 |
% |
Net income attributable to Ardent Health Partners, Inc. |
$ |
96,139 |
|
|
2.2 |
% |
|
$ |
58,057 |
|
|
1.4 |
% |
|
|
|
|
|
|
|
|
||||||
Net income per share: |
|
|
|
|
|
|
|
||||||
Basic |
$ |
0.74 |
|
|
|
|
$ |
0.46 |
|
|
|
||
Diluted |
$ |
0.74 |
|
|
|
|
$ |
0.46 |
|
|
|
||
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
||||||
Basic |
|
129,877,510 |
|
|
|
|
|
126,115,301 |
|
|
|
||
Diluted |
|
130,022,643 |
|
|
|
|
|
126,115,301 |
|
|
|
||
Ardent Health Partners, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited; Dollars in thousands) |
|||||||
|
Nine Months Ended
|
||||||
|
|
2024 |
|
|
|
2023 |
|
Cash flows from operating activities: |
|
|
|
||||
Net income |
$ |
158,817 |
|
|
$ |
118,196 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
|
108,434 |
|
|
|
104,860 |
|
Other non-operating gains |
|
— |
|
|
|
(45 |
) |
Loss on extinguishment and modification of debt |
|
2,158 |
|
|
|
— |
|
Amortization of deferred financing costs and debt discounts |
|
4,235 |
|
|
|
4,266 |
|
Deferred income taxes |
|
1,690 |
|
|
|
5,346 |
|
Equity-based compensation |
|
8,873 |
|
|
|
723 |
|
Loss from non-consolidated affiliates |
|
2,160 |
|
|
|
3,622 |
|
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures: |
|
|
|
||||
Accounts receivable |
|
77,284 |
|
|
|
(54,896 |
) |
Inventories |
|
(2,545 |
) |
|
|
(556 |
) |
Prepaid expenses and other current assets |
|
(21,189 |
) |
|
|
(20,450 |
) |
Accounts payable and other accrued expenses and liabilities |
|
(132,031 |
) |
|
|
9,996 |
|
Accrued salaries and benefits |
|
(12,429 |
) |
|
|
(16,863 |
) |
Net cash provided by operating activities |
|
195,457 |
|
|
|
154,199 |
|
Cash flows from investing activities: |
|
|
|
||||
Investment in acquisitions, net of cash acquired |
|
(8,044 |
) |
|
|
— |
|
Purchases of property and equipment |
|
(106,234 |
) |
|
|
(79,959 |
) |
Other |
|
(738 |
) |
|
|
(1,318 |
) |
Net cash used in investing activities |
|
(115,016 |
) |
|
|
(81,277 |
) |
Cash flows from financing activities: |
|
|
|
||||
Proceeds from initial public offering, net of underwriting discounts and commissions |
|
208,656 |
|
|
|
— |
|
Proceeds from insurance financing arrangements |
|
10,797 |
|
|
|
24,749 |
|
Proceeds from long-term debt |
|
3,600 |
|
|
|
1,225 |
|
Payments of principal on insurance financing arrangements |
|
(7,370 |
) |
|
|
(15,885 |
) |
Payments of principal on long-term debt |
|
(106,335 |
) |
|
|
(10,549 |
) |
Debt issuance costs |
|
(2,450 |
) |
|
|
— |
|
Payments of initial public offering costs |
|
(8,636 |
) |
|
|
— |
|
Distributions to noncontrolling interests |
|
(53,138 |
) |
|
|
(50,677 |
) |
Redemption of equity attributable to noncontrolling interests |
|
— |
|
|
|
(26,024 |
) |
Other |
|
— |
|
|
|
(7,209 |
) |
Net cash provided by (used in) financing activities |
|
45,124 |
|
|
|
(84,370 |
) |
Net increase (decrease) in cash and cash equivalents |
|
125,565 |
|
|
|
(11,448 |
) |
Cash and cash equivalents at beginning of year |
|
437,577 |
|
|
|
456,124 |
|
Cash and cash equivalents at end of year |
$ |
563,142 |
|
|
$ |
444,676 |
|
|
|
|
|
||||
Supplemental Cash Flow Information: |
|
|
|
||||
Non-cash purchases of property and equipment |
$ |
5,546 |
|
|
$ |
13,188 |
|
Offering costs not yet paid |
$ |
898 |
|
|
$ |
— |
|
Ardent Health Partners, Inc. Condensed Consolidated Balance Sheets (Unaudited; Dollars in thousands) |
|||||
|
September 30,
|
|
December 31,
|
||
Assets |
|
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents |
$ |
563,142 |
|
$ |
437,577 |
Accounts receivable |
|
705,747 |
|
|
775,452 |
Inventories |
|
108,231 |
|
|
105,485 |
Prepaid expenses |
|
119,956 |
|
|
77,281 |
Other current assets |
|
193,616 |
|
|
222,290 |
Total current assets |
|
1,690,692 |
|
|
1,618,085 |
Property and equipment, net |
|
814,860 |
|
|
811,089 |
Operating lease right of use assets |
|
261,214 |
|
|
260,003 |
Operating lease right of use assets, related party |
|
932,246 |
|
|
941,150 |
Goodwill |
|
852,001 |
|
|
844,704 |
Other intangible assets, net |
|
76,930 |
|
|
76,930 |
Deferred income taxes |
|
34,764 |
|
|
32,491 |
Other assets |
|
137,307 |
|
|
147,106 |
Total assets |
$ |
4,800,014 |
|
$ |
4,731,558 |
|
|
|
|
||
Liabilities and Equity |
|
|
|
||
Current liabilities: |
|
|
|
||
Current installments of long-term debt |
$ |
12,167 |
|
$ |
18,605 |
Accounts payable |
|
368,850 |
|
|
474,543 |
Accrued salaries and benefits |
|
255,370 |
|
|
267,685 |
Other accrued expenses and liabilities |
|
250,945 |
|
|
233,271 |
Total current liabilities |
|
887,332 |
|
|
994,104 |
Long-term debt, less current installments |
|
1,083,725 |
|
|
1,168,253 |
Long-term operating lease liability |
|
233,786 |
|
|
235,241 |
Long-term operating lease liability, related party |
|
922,665 |
|
|
932,090 |
Self-insured liabilities |
|
231,951 |
|
|
243,552 |
Other long-term liabilities |
|
53,686 |
|
|
76,002 |
Total liabilities |
|
3,413,145 |
|
|
3,649,242 |
|
|
|
|
||
Redeemable noncontrolling interests |
|
2,391 |
|
|
7,302 |
Equity: |
|
|
|
||
Common units, no and unlimited units authorized as of September 30, 2024 and December 31, 2023, respectively; no and 484,922,828 units issued and outstanding as of September 30, 2024 and December 31, 2023, respectively |
|
— |
|
|
496,882 |
Preferred stock, par value |
|
— |
|
|
— |
Common stock, par value |
|
1,428 |
|
|
— |
Additional paid in capital |
|
743,364 |
|
|
— |
Accumulated other comprehensive income |
|
9,486 |
|
|
18,561 |
Retained earnings |
|
251,592 |
|
|
155,453 |
Equity attributable to Ardent Health Partners, Inc. |
|
1,005,870 |
|
|
670,896 |
Noncontrolling interests |
|
378,608 |
|
|
404,118 |
Total equity |
|
1,384,478 |
|
|
1,075,014 |
Total liabilities and equity |
$ |
4,800,014 |
|
$ |
4,731,558 |
| (1) |
As of September 30, 2024 and December 31, 2023, the unaudited condensed consolidated balance sheet included total liabilities of consolidated variable interest entities of |
Ardent Health Partners, Inc. Operating Statistics (Unaudited) |
|||||||||||||||||
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||||
|
|
2024 |
|
% Change |
|
2023 |
|
|
|
2024 |
|
% Change |
|
2023 |
|
||
|
|
|
|
|
|
|
|
||||||||||
Total revenue (in thousands) |
$ |
1,449,817 |
|
5.2 |
% |
$ |
1,377,727 |
|
|
$ |
4,359,783 |
|
7.3 |
% |
$ |
4,063,449 |
|
Hospitals operated (at period end) (1) |
|
30 |
|
(3.2 |
)% |
|
31 |
|
|
|
30 |
|
(3.2 |
)% |
|
31 |
|
Licensed beds (at period end) (2) |
|
4,287 |
|
(0.8 |
)% |
|
4,323 |
|
|
|
4,287 |
|
(0.8 |
)% |
|
4,323 |
|
Utilization of licensed beds (3) |
|
46 |
% |
4.5 |
% |
|
44 |
% |
|
|
46 |
% |
2.2 |
% |
|
45 |
% |
Admissions (4) |
|
39,568 |
|
6.4 |
% |
|
37,191 |
|
|
|
116,995 |
|
5.6 |
% |
|
110,754 |
|
Adjusted admissions (5) |
|
86,833 |
|
3.8 |
% |
|
83,643 |
|
|
|
254,909 |
|
3.5 |
% |
|
246,298 |
|
Inpatient surgeries (6) |
|
8,871 |
|
0.5 |
% |
|
8,826 |
|
|
|
26,829 |
|
0.3 |
% |
|
26,751 |
|
Outpatient surgeries (7) |
|
23,220 |
|
0.2 |
% |
|
23,164 |
|
|
|
69,201 |
|
(1.7 |
)% |
|
70,417 |
|
Emergency room visits (8) |
|
161,343 |
|
2.6 |
% |
|
157,182 |
|
|
|
475,212 |
|
3.7 |
% |
|
458,160 |
|
Patient days (9) |
|
182,023 |
|
4.8 |
% |
|
173,687 |
|
|
|
540,196 |
|
2.6 |
% |
|
526,634 |
|
Total encounters (10) |
|
1,482,655 |
|
7.5 |
% |
|
1,378,599 |
|
|
|
4,304,097 |
|
4.7 |
% |
|
4,109,144 |
|
Average length of stay (11) |
|
4.60 |
|
(1.5 |
)% |
|
4.67 |
|
|
|
4.62 |
|
(2.7 |
)% |
|
4.75 |
|
Net patient service revenue per adjusted admission (12) |
$ |
16,312 |
|
0.9 |
% |
$ |
16,174 |
|
|
$ |
16,784 |
|
3.6 |
% |
$ |
16,206 |
|
| (1) |
Hospitals operated (at period end). This metric represents the total number of hospitals operated by us at the end of the applicable period, irrespective of whether the hospital real estate is (i) owned by us, (ii) leased by us or (iii) held through a controlling interest in a JV. This metric includes the managed clinical operations of the hospital at UT Health North Campus in |
|
On April 30, 2024, we closed UT Health East Texas Specialty Hospital, a long-term acute care hospital (the “LTAC Hospital”) in |
||
| (2) | Licensed beds (at period end). This metric represents the total number of beds for which the appropriate state agency licenses a facility, regardless of whether the beds are actually available for patient use. |
|
| (3) | Utilization of licensed beds. This metric represents a measure of the actual utilization of our inpatient facilities, computed by (i) dividing patient days by the number of days in each period, and (ii) further dividing that number by average licensed beds, which is calculated by dividing total licensed beds (at period end) by the number of days in the period, multiplied by the number of days in the period the licensed beds were in existence. |
|
| (4) | Admissions. This metric represents the number of patients admitted for inpatient treatment during the applicable period. |
|
| (5) | Adjusted admissions. This metric is used by management as a general measure of combined inpatient and outpatient volume. Adjusted admissions provides management with a key performance indicator that considers both inpatient and outpatient volumes by applying an inpatient volume measure (admissions) to a ratio of gross inpatient and outpatient revenue to gross inpatient revenue. Gross inpatient and outpatient revenue reflect gross inpatient and outpatient charges prior to estimated contractual adjustments, uninsured discounts, implicit price concessions, and other discounts. The calculation of adjusted admissions is summarized as follows: |
|
Adjusted Admissions = Admissions x (Gross Inpatient Revenue + Gross Outpatient Revenue) |
||
Gross Inpatient Revenue |
||
| (6) | Inpatient surgeries. This metric represents the number of surgeries performed on patients who have been admitted to our hospitals. Pain management, c-sections, and certain diagnostic procedures are excluded from inpatient surgeries. |
|
| (7) | Outpatient surgeries. This metric represents the number of surgeries performed on patients who have not been admitted to our hospitals. Pain management, c-sections, and certain diagnostic procedures are excluded from outpatient surgeries. |
|
| (8) | Emergency room visits. This metric represents the total number of patients provided with emergency room treatment during the applicable period. |
|
| (9) | Patient days. This metric represents the total number of days of care provided to patients admitted to our hospitals during the applicable period. |
|
| (10) | Total encounters. This metric represents the total number of events where healthcare services are rendered resulting in a billable event during the applicable period. This includes both hospital and ambulatory patient interactions. |
|
| (11) | Average length of stay. This metric represents the average number of days admitted patients stay in our hospitals. |
|
| (12) | Net patient service revenue per adjusted admission. This metric represents net patient service revenue divided by adjusted admissions for the applicable period. Net patient service revenue reflects gross inpatient and outpatient charges less estimated contractual adjustments, uninsured discounts, implicit price concessions, and other discounts. |
Ardent Health Partners, Inc. Supplemental Non-GAAP Disclosures (Unaudited; Dollars in thousands) |
|||||||||||||||
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Net income |
$ |
46,005 |
|
|
$ |
38,708 |
|
|
$ |
158,817 |
|
|
$ |
118,196 |
|
Adjusted EBITDA Addbacks: |
|
|
|
|
|
|
|
||||||||
Income tax expense |
|
11,062 |
|
|
|
7,261 |
|
|
|
36,997 |
|
|
|
24,591 |
|
Interest expense, net |
|
14,629 |
|
|
|
19,041 |
|
|
|
52,050 |
|
|
|
55,854 |
|
Depreciation and amortization |
|
36,771 |
|
|
|
35,488 |
|
|
|
108,434 |
|
|
|
104,860 |
|
Noncontrolling interest earnings |
|
(19,683 |
) |
|
|
(17,870 |
) |
|
|
(62,678 |
) |
|
|
(60,139 |
) |
Loss on extinguishment and modification of debt |
|
1,490 |
|
|
|
— |
|
|
|
3,388 |
|
|
|
— |
|
Other non-operating losses (gains) (1) |
|
47 |
|
|
|
— |
|
|
|
(208 |
) |
|
|
(522 |
) |
Cybersecurity Incident recoveries, net (2) |
|
(4,976 |
) |
|
|
— |
|
|
|
(4,976 |
) |
|
|
— |
|
Restructuring, exit and acquisition-related costs (3) |
|
3,796 |
|
|
|
1,511 |
|
|
|
11,694 |
|
|
|
11,473 |
|
Epic expenses (4) |
|
485 |
|
|
|
437 |
|
|
|
1,500 |
|
|
|
1,415 |
|
Equity-based compensation |
|
8,135 |
|
|
|
181 |
|
|
|
8,873 |
|
|
|
723 |
|
Loss (income) from disposed operations |
|
3 |
|
|
|
3 |
|
|
|
1,989 |
|
|
|
(65 |
) |
Adjusted EBITDA |
$ |
97,764 |
|
|
$ |
84,760 |
|
|
$ |
315,880 |
|
|
$ |
256,386 |
|
| (1) | Other non-operating losses (gains) include gains and losses realized on certain non-recurring events or events that are non-operational in nature, including gains realized on certain asset divestitures. |
|
| (2) | Cybersecurity Incident recoveries, net represents insurance recovery proceeds associated with the Cybersecurity Incident, net of incremental information technology and litigation costs. |
|
| (3) |
Restructuring, exit and acquisition-related costs represent (i) enterprise restructuring costs, including severance costs related to work force reductions of |
|
| (4) |
Epic expenses consist of various costs incurred in connection with the implementation of Epic, our health information technology system. These costs included professional fees of |
Ardent Health Partners, Inc. Supplemental Non-GAAP Disclosures (Unaudited; Dollars in thousands) |
|||||||
|
Three Months
|
|
Nine Months
|
||||
|
|
2024 |
|
|
|
2024 |
|
Net income |
$ |
46,005 |
|
|
$ |
158,817 |
|
Adjusted EBITDAR Addbacks: |
|
|
|
||||
Income tax expense |
|
11,062 |
|
|
|
36,997 |
|
Interest expense, net |
|
14,629 |
|
|
|
52,050 |
|
Depreciation and amortization |
|
36,771 |
|
|
|
108,434 |
|
Noncontrolling interest earnings |
|
(19,683 |
) |
|
|
(62,678 |
) |
Loss on extinguishment and modification of debt |
|
1,490 |
|
|
|
3,388 |
|
Other non-operating losses (gains) (1) |
|
47 |
|
|
|
(208 |
) |
Cybersecurity Incident recoveries, net (2) |
|
(4,976 |
) |
|
|
(4,976 |
) |
Restructuring, exit and acquisition-related costs (3) |
|
3,796 |
|
|
|
11,694 |
|
Epic expenses (4) |
|
485 |
|
|
|
1,500 |
|
Equity-based compensation |
|
8,135 |
|
|
|
8,873 |
|
Loss from disposed operations |
|
3 |
|
|
|
1,989 |
|
Rent expense payable to REITs (5) |
|
40,056 |
|
|
|
119,826 |
|
Adjusted EBITDAR |
$ |
137,820 |
|
|
$ |
435,706 |
|
(1) |
Other non-operating losses (gains) include gains and losses realized on certain non-recurring events or events that are non-operational in nature, including gains realized on certain asset divestitures. |
|
(2) |
Cybersecurity Incident recoveries, net represents insurance recovery proceeds associated with the Cybersecurity Incident, net of incremental information technology and litigation costs. |
|
(3) |
Restructuring, exit and acquisition-related costs represent (i) enterprise restructuring costs, including severance costs related to work force reductions of |
|
(4) |
Epic expenses consist of various costs incurred in connection with the implementation of Epic, our health information technology system. These costs included professional fees of |
|
(5) |
Rent expense payable to REITs consists of rent expense of |
Ardent Health Partners, Inc. Supplemental Non-GAAP Disclosures (Unaudited; Dollars in millions) |
|||||||
|
For the Full Year Ending
|
||||||
|
Low |
|
High |
||||
Net income |
$ |
241 |
|
|
$ |
263 |
|
Adjusted EBITDA Addbacks: |
|
|
|
||||
Income tax expense |
|
39 |
|
|
|
45 |
|
Interest expense, net |
|
66 |
|
|
|
65 |
|
Depreciation and amortization |
|
145 |
|
|
|
144 |
|
Noncontrolling interest earnings |
|
(85 |
) |
|
|
(87 |
) |
Loss on extinguishment and modification of debt |
|
3 |
|
|
|
3 |
|
Cybersecurity Incident recoveries, net (1) |
|
(20 |
) |
|
|
(25 |
) |
Restructuring, exit and acquisition-related costs |
|
13 |
|
|
|
12 |
|
Epic expenses |
|
4 |
|
|
|
3 |
|
Equity-based compensation |
|
17 |
|
|
|
17 |
|
Loss from disposed operations |
|
2 |
|
|
|
— |
|
Adjusted EBITDA |
$ |
425 |
|
|
$ |
440 |
|
| (1) | Cybersecurity Incident recoveries, net represents insurance recovery proceeds associated with the Cybersecurity Incident, net of incremental information technology and litigation costs. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106312222/en/
Media Relations:
Rebecca Kirkham
Ardent Health
rebecca.kirkham@ardenthealth.com
(615) 296-3000
Investor Relations:
Dave Styblo
Ardent Health
Investor.Relations@ardenthealth.com
(615) 296-3016
Source: Ardent Health
FAQ
What was Ardent Health's (ARDT) revenue in Q3 2024?
How much did Ardent Health (ARDT) earn per share in Q3 2024?
What is Ardent Health's (ARDT) updated revenue guidance for 2024?
How much did Ardent Health's (ARDT) admissions grow in Q3 2024?
